on GENFIT (EPA:GNFT)
GENFIT Highlights Advances in ACLF and MASH Diagnostics at AASLD 2026
GENFIT, a biopharmaceutical firm, announced its participation at AASLD The Liver Meeting® 2026, showcasing advancements in Acute on-Chronic Liver Failure (ACLF) and Metabolic dysfunction-associated steatohepatitis (MASH) diagnostics. Scheduled scientific events and presentations will explore the company's progress.
GENFIT's strategy for ACLF includes progressing nangibotide into Phase 2 trials. Three presentations will highlight treatments for inflammation and immune issues in liver failure, emphasizing nitazoxanide's potential. Engagement with NACSELD will deepen scientific dialogue.
On MASH diagnostics, GENFIT leads discussions at the Global Liver Institute’s forum. non-invasive techniques and NIS™ Technology will be discussed, highlighting their role in early detection and treatment monitoring.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news